Funding for this research was provided by:
National Human Genome Research Institute (K99-HG009920-01)
Canadian Institutes of Health Research (Fellowship)
National Institutes of Health (5 F32 AI129249, RM1HG006193, R01HG008131-01)
Klarman Cell Observatory, Broad Institute (Klarman Cell Observatory)
Howard Hughes Medical Institute (Investigator)
Article History
Received: 25 October 2019
Accepted: 14 May 2020
First Online: 3 June 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: AR is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and an SAB member of ThermoFisher Scientific, Neogene Therapeutics, Asimov, and Syros Pharmaceuticals. NH is a co-founder of Neon Therapeutics, and equity holder in BioNTech, and consultant for Related Sciences. All other authors declare no competing interests.